SCHEMBL29447948

SCHEMBL29447948

OCC1Cc2ccccc2C1

nearest known ligand 0.47

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.47
CYP19A1 P11511 2/20 0.47
GBA1 P04062 1/20 0.41
ADRA2A P08913 1/20 0.41
MAPT P10636 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
DRD3 P35462 1/20 0.39
PLAU P00749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL835059 1.00 IDO1 (0.47) IDO1CYP19A1GBA1ADRA2AMAPT
SCHEMBL7214515 0.85 CA1 (0.43) IDO1CYP19A1MAPT
SCHEMBL1689627 0.84 CYP19A1 (0.54) CYP19A1GBA1SIGMAR1PLAU
SCHEMBL15701675 0.84 CYP19A1 (0.54) CYP19A1GBA1SIGMAR1PLAU
SCHEMBL6570371 0.84 CYP19A1 (0.54) CYP19A1GBA1SIGMAR1PLAU
SCHEMBL29633580 0.80 IDO1 (0.53) IDO1CYP19A1GBA1ADRA2AMAPT
SCHEMBL1338863 0.80 IDO1 (0.53) IDO1CYP19A1GBA1ADRA2AMAPT
SCHEMBL8962547 0.79 ESR2 (0.34) CYP19A1
SCHEMBL12472556 0.78 DGAT1 (0.45)
SCHEMBL10530881 0.77 IDO1 (0.50) IDO1CYP19A1GBA1ADRA2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120091758-A Arthropod control composition 弗门尼舍有限公司 2025-06-03 CN claimed
CN-113873884-B Arthropod control composition 弗门尼舍有限公司 2024-06-14 CN claimed
CN-120091758-A Arthropod control composition 弗门尼舍有限公司 2025-06-03 CN disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 CN disclosed
CN-113873884-B Arthropod control composition 弗门尼舍有限公司 2024-06-14 CN disclosed
US-11744785-B2 Use of volatile compositions to limit or eliminate the perception of malodor FIRMENICH SA (CH) 2023-09-05 US disclosed
US-20230233425-A1 USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR FIRMENICH SA (CH) 2023-07-27 US disclosed
EP-3966199-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2022-03-16 EP disclosed
CN-114174263-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2022-03-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744785-B2 Use of volatile compositions to limit or eliminate the perception of malodor TAS2R8, TRPA1, TAS2R10 IDO1 3588/4885CYP19A1 2700/4885GBA1 2884/4885
US-20230233425-A1 USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR TAS2R8, TRPA1, TAS2R10 IDO1 3588/4885CYP19A1 2700/4885GBA1 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.